keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma recent advances

keyword
https://www.readbyqxmd.com/read/28548930/comparison-of-treatment-outcome-between-living-donor-liver-transplantation-and-sorafenib-for-patients-with-hepatocellular-carcinoma-beyond-the-milan-criteria
#1
Yuri Cho, Jeong-Hoon Lee, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Nam-Joon Yi, Kwang-Woong Lee, Yoon Jun Kim, Jung-Hwan Yoon, Kyung-Suk Suh
For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after living-donor liver transplantation (LDLT), even though they are beyond the Milan criteria. In the present study, we investigated whether LDLT offers a better treatment outcome than sorafenib for patients with HCC beyond the Milan criteria according to the MoRAL score...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28545181/hepatocellular-carcinoma-a-comprehensive-review-of-biomarkers-clinical-aspects-and-therapy
#2
Nathalia Martines Tunissiolli, Márcia Maria Urbanin Castanhole-Nunes, Patrícia Matos Biselli-Chicote, Érika Cristina Pavarino, Renato Ferreira da Silva, Rita de Cássia Martins Alves da Silva, Eny Maria Goloni-Bertollo
Hepatocellular carcinoma (HCC) is a cause of several deaths related to cancer worldwidely. In early stage, curative treatments such as surgical resection, liver transplant and local ablation can improve the patient ´s survival. However, the disease is detected in advanced stage; moreover some available therapies are restricted to palliative care and local treatment. Early detections of HCC and adequate therapy are crucial to increase survival as well as to improve the patient´s quality of life. Therefore, researchers have been investigating molecular biomarkers with high sensibility and reliability as Golgi 73 protein (GP73), Glypican-3 (GPC3), Osteopontin (OPN), microRNAs and others...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28522682/regorafenib-approved-for-liver-cancer
#3
(no author information available yet)
The FDA recently expanded label indications for regorafenib to include treating patients with advanced hepatocellular carcinoma whose disease has progressed on the standard of care, sorafenib. Until now, these patients have had no other treatment options. Regorafenib is the first drug to be approved for liver cancer in a decade.
May 18, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28515345/genetic-factors-associated-with-risk-of-metabolic-syndrome-and-hepatocellular-carcinoma
#4
REVIEW
Ranran Tang, Heng Liu, Yingdi Yuan, Kaipeng Xie, Pengfei Xu, Xiaoyun Liu, Juan Wen
Although the metabolic syndrome is a commonplace topic, its potential threats to public health is a problem that cannot be neglected. As the living conditions improved significantly over the past few years, the morbidity of metabolic syndrome has also steadily risen, and the onset age is becoming younger. The hepatocellular carcinoma (HCC), is one of the most prevalent life-threatening human cancers worldwide, incidence of which is also on the rise, gradually occupied the top of the list associated with metabolic syndrome related complication...
May 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28509806/advances-in-management-of-hepatocellular-carcinoma
#5
Manon Allaire, Jean-Charles Nault
PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC) is one of the leading causes of death by cancer worldwide due to a dismal prognosis. The aim of this review is to summarize the main advances in the pathophysiology and management of HCC. RECENT FINDINGS: Genomic analysis has recently delineated the key signaling pathways aberrantly deregulated in HCC (telomere maintenance, cell cycle gene, Wnt/β-catenin, epigenetic modifier, oxidative stress etc.). Major advances in the clinical care of patients with HCC are helping to refine the diagnosis algorithm and tumor staging...
May 15, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28506080/hepatocellular-carcinoma-treatment-a-comparative-review-of-emerging-growth-factor-receptor-antagonists
#6
Su Jin Lee, Ho Yeong Lim
Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Over the last decade, sorafenib has been the only available therapeutic option for advanced HCC, although regorafenib recently showed a survival benefit compared with placebo in a second-line setting. Areas covered: This review discusses key published and ongoing studies with targeted agents in HCC, molecular targets of HCC, the mechanism of resistance to sorafenib, and the role of biomarker-enriched clinical trials. Expert opinion: The multiplicity of drivers and the existence of substantial molecular heterogeneity limit the benefits of targeted therapies in HCC...
May 16, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28489585/pou2f1-over-expression-correlates-with-poor-prognoses-and-promotes-cell-growth-and-epithelial-to-mesenchymal-transition-in-hepatocellular-carcinoma
#7
Yonghao Zhong, Hongyang Huang, Min Chen, Jinzhou Huang, Qingxia Wu, Guang-Rong Yan, De Chen
Despite recent efforts to understand activities of POU domain class 2 transcription factor 1 (POU2F1), little is known about the roles of POU2F1 in hepatocellular carcinoma (HCC) tumorigenesis and its correlation with any clinicopathological feature of HCC. In this study, we found that POU2F1 was significantly up-regulated in HCC specimens compared with adjacent non-cancerous liver specimens. The high POU2F1 protein expression level positively correlated with large tumor size, high histological grade, tumor metastasis and advanced clinical stage, and HCC patients with high POU2F1 levels exhibited poor prognoses...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28487602/hepatitis-b-virus-infection-and-alcohol-consumption
#8
REVIEW
Ayako Iida-Ueno, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the second most common cause of cancer deaths worldwide. The top three causes of HCC are hepatitis B virus (HBV), hepatitis C virus (HCV), and alcoholic liver disease. Owing to recent advances in direct-acting antiviral agents, HCV can now be eradicated in almost all patients. HBV infection and alcoholic liver disease are expected, therefore, to become the leading causes of HCC in the future. However, the association between alcohol consumption and chronic hepatitis B in the progression of liver disease is less well understood than with chronic hepatitis C...
April 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28482674/management-of-hepatocellular-in-the-united-states
#9
Ali A Mokdad, Caitlin A Hester, Amit G Singal, Adam C Yopp
Hepatocellular carcinoma (HCC) is a major cause of cancer burden globally. In the United States, the incidence of HCC is forecast to continue to rise for the next 15 years. Patients with HCC vary markedly owing to heterogeneous tumor characteristics and concomitant liver dysfunction. In the United States and Europe, HCC is staged and managed according to the Barcelona Clinic Liver Cancer (BCLC) system. For very early and early stage HCC, or BCLC 0/A, liver transplant is the optimal treatment option. Liver resection and radiofrequency or microwave ablation are alternative treatment options...
April 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28482403/-recent-advances-in-the-treatment-of-hepatitis-c-in-2016
#10
B F Luo, L Wei
It has been rapidly developed in treatment of chronic hepatitis C from the past few years. Here we summarize the progress in chronic hepatitis C treatment in 2016. We introduce the pan-genotypic regimens with short-duration, the efficacy of DAA regimens in difficult-to-treat population, the influence on hepatocellular carcinoma, decompensation of liver cirrhosis, liver fibrosis and liver transplantation, the safety of DAA regimens in special population, information from real-world studies and data from China...
March 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28480064/systemic-therapy-for-advanced-hepatocellular-carcinoma-an-update
#11
REVIEW
Jasmin Radhika Desai, Sebastian Ochoa, Petra Alexandra Prins, Aiwu Ruth He
Advanced hepatocellular carcinoma (HCC) is a deadly disease with few systemic therapeutic options. Sorafenib is the only agent to be FDA approved for the first-line treatment of patients with HCC. This drug increases overall survival (OS) by 3 months compared with placebo (10.7 months with sorafenib vs. 7.7 months with placebo). More recently, the RESORCE trial demonstrated efficacy of regorafenib in the second-line treatment of HCC: OS was increased from 7.8 months with placebo to 10.6 months with regorafenib after patients experienced disease progression on sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#12
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28475115/androgen-receptor-could-be-a-potential-therapeutic-target-in-patients-with-advanced-hepatocellular-carcinoma
#13
Tatsuo Kanda, Koji Takahashi, Masato Nakamura, Shingo Nakamoto, Shuang Wu, Yuki Haga, Reina Sasaki, Xia Jiang, Osamu Yokosuka
Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC. Previous studies have shown that androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the development of HCC. Here, we discuss the recent data on AR and HCC, and the combination of sorafenib and inhibitors of AR for advanced-HCC patients. Androgen-dependent and androgen-independent AR activation exist in human hepatocarcinogenesis...
May 5, 2017: Cancers
https://www.readbyqxmd.com/read/28474222/serum-hmgb1-concentrations-at-4%C3%A2-weeks-is-a-useful-predictor-of-extreme-poor-prognosis-for-advanced-hepatocellular-carcinoma-treated-with-sorafenib-and-hepatic-arterial-infusion-chemotherapy
#14
Kazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, Tomokazu Kawaoka, C Nelson Hayes, Yuji Teraoka, Kana Daijo, Yuki Nakamura-Inagaki, Kei Morio, Hatsue Fujino, Hiromi Kan, Takuro Uchida, Keiichi Masaki, Tomoki Kobayashi, Takashi Nakahara, Grace Naswa Makokha, Yizhou Zhang, Yuko Nagaoki, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiromi Abe-Chayama, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama
BACKGROUND: Biomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated with poor prognosis for patients with HCC. The purpose of this study was to assess serum HMGB1 concentrations before and during sorafenib treatment or hepatic arterial infusion chemotherapy (HAIC) and to explore the ability of serum HMGB1 concentrations to predict prognosis...
May 4, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28465155/effect-of-liver-disease-on-hepatic-transporter-expression-and-function
#15
REVIEW
Nilay Thakkar, Jason R Slizgi, Kim L R Brouwer
Liver disease can alter the disposition of xenobiotics and endogenous substances. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) recommend, if possible, studying the effect of liver disease on drugs under development to guide specific dose recommendations in these patients. While extensive research has been conducted to characterize the effect of liver disease on drug-metabolizing enzymes, emerging data have implicated that the expression and/or function of hepatobiliary transport proteins also are altered in liver disease...
April 29, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28462693/sarcopenia-in-patients-with-advanced-liver-disease
#16
Francesca Romana Ponziani, Antonio Gasbarrini
Sarcopenia is the loss of muscle mass and function, affecting up to 70% of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients...
April 28, 2017: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/28460616/epithelial-to-mesenchymal-transition-a-mediator-of-sorafenib-resistance-in-advanced-hepatocellular-carcinoma
#17
Nabiel Mir, Aparna Jayachandran, Bijay Dhungel, Ritu Shrestha, Jason C Steel
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide and its incidence is steadily rising. Currently, sorafenib remains the only approved standard treatment for patients with advanced HCC, as it has proven to increase survival in these patients. However, clinical and preclinical observations indicate that sorafenib treatment may have limited efficacy due to tumor progression from the rapid development of acquired resistance. Elucidation of the underlying mechanisms of evasive resistance to sorafenib is a major challenge in HCC research...
April 26, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28460481/shp2-is-induced-by-the-hbx-nf-%C3%AE%C2%BAb-pathway-and-contributes-to-fibrosis-during-human-early-hepatocellular-carcinoma-development
#18
Hyo Jeong Kang, Dal-Hee Chung, Chang Ohk Sung, Su Hyun Yoo, Eunsil Yu, Nayoung Kim, Sy-Hye Lee, Ji-Young Song, Chong Jai Kim, Jene Choi
The non-receptor tyrosine phosphatase SHP2 has scaffolding functions in signal transduction cascades downstream of growth receptors. A recent study suggested that SHP2 acts as a tumor suppressor during hepatocellular carcinoma (HCC) development. Herein we examined whether SHP2 links the HBx-NF-κB pathway to EGFR signaling during HCC development. The overexpression of HBx or NF-κB led to increased SHP2 expression via NF-κB binding to the Shp2 promoter. EGF treatment induced ERK activation as well as the rapid assembly of SHP2, EGFR, and Gab1...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445959/brain-metastases-from-hepatocellular-carcinoma-recent-advances-and-future-avenues
#19
REVIEW
Shanshan Wang, Anqiang Wang, Jianzhen Lin, Yuan Xie, Liangcai Wu, Hanchun Huang, Jin Bian, Xiaobo Yang, Xueshuai Wan, Haitao Zhao, Jiefu Huang
The incidence of brain metastases from hepatocellular carcinoma (BMHCC) is becoming more frequent than that of the past as a result of prolonged survival of patients with HCC. Compared with brain metastases from other types of cancer, BMHCC tends to exhibit a high incidence of intracerebral hemorrhage (ICH) and poor liver function. Unfortunately, the prognosis is extremely poor for patients with BMHCC owing to the limited treatment selection. Currently, optimal treatment requires multidisciplinary approaches including surgery, whole-brain radiation therapy and stereotactic radiosurgery...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28430610/treatment-of-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-advances-and-challenges
#20
REVIEW
Jin-Fang Jiang, Yong-Cong Lao, Bao-Hong Yuan, Jun Yin, Xin Liu, Long Chen, Jian-Hong Zhong
Portal vein tumor thrombus is a frequent, challenging complication in hepatocellular carcinoma. Hepatocellular carcinoma patients with portal vein tumor thrombus may show worse liver function, less treatment tolerance and worse prognosis than patients without portal vein tumor thrombus, and they may be at higher risk of comorbidity related to portal hypertension. Western and some Asian guidelines stratify hepatocellular carcinoma with portal vein tumor thrombus together with metastatic hepatocellular carcinoma and therefore recommend only palliative treatment with sorafenib or other systemic agents...
May 16, 2017: Oncotarget
keyword
keyword
69280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"